Today: 19 May 2026
Browse Category

NASDAQ:BHVN 14 August 2025 - 5 November 2025

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven Ltd. shares plunged about 40% on Nov. 5, 2025, after the FDA rejected its lead drug VYGLXIA for spinocerebellar ataxia, citing trial design and data issues. The company will cut R&D spending by 60% and halt non-priority programs. Analysts downgraded the stock, which now trades near $8–9, down over 70% year-over-year. Biohaven reported a $198 million net loss in Q2 with $408 million in cash.
5 November 2025
·
Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

Miracle Cure, Mega-Deals & Vaccine Drama: Global Biotech & Health Roundup (Aug 13–14, 2025)

The FDA approved Insmed’s brensocatib as the first therapy for non-cystic fibrosis bronchiectasis, following positive results in a 1,700-patient trial. Novartis reported Phase 3 successes for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. In China, RemeGen’s telitacicept met its main goal in a Phase 3 Sjögren’s trial. Response Pharmaceuticals’ RDX-002 showed weight-loss maintenance in post-GLP-1 patients.
14 August 2025
···

Stock Market Today

  • Yacktman Asset Management Cuts Alphabet Inc. Stake Amid Mixed Institutional Moves
    May 19, 2026, 2:13 PM EDT. Yacktman Asset Management LP reduced its stake in Alphabet Inc. (NASDAQ:GOOG) by 3.1% in Q4, selling 36,606 shares and holding 1,129,807 shares valued at $354.5 million, representing 5% of its portfolio. Other institutional investors showed varied activity with Brighton Jones LLC and Worldquant Millennium Advisors LLC increasing their holdings significantly. Alphabet's stock saw multiple analyst ratings, including 'outperform' and 'buy' with target prices ranging from $345 to $450, reflecting positive sentiment from firms like Scotiabank, TD Cowen, and Deutsche Bank. Institutional investors own 27.26% of Alphabet's shares. The stock remains a top focus amid ongoing trading by hedge funds and asset managers.

Latest articles

Why Recursion Stock Just Hit a 52-Week Low — and the FDA Update Traders Are Waiting For

Why Recursion Stock Just Hit a 52-Week Low — and the FDA Update Traders Are Waiting For

19 May 2026
Recursion Pharmaceuticals shares fell 2.2% to $2.825 Tuesday, hitting a 52-week low of $2.77, after reporting first-quarter revenue of $6.47 million, down from $14.75 million a year earlier. Net loss narrowed to $117.5 million. Early clinical data for REC-1245 showed no dose-limiting toxicities in 16 solid-tumor patients. The company ended March with $665.2 million in cash.
Wall Street’s Top Picks for U.S. Stocks as Yields Stay High

Wall Street’s Top Picks for U.S. Stocks as Yields Stay High

19 May 2026
U.S. stocks fell Tuesday as the 10-year Treasury yield reached its highest point since January 2025, pressuring growth shares. Nvidia drew the most attention ahead of its earnings, with options markets pricing in a possible $355 billion swing in value. Dell highlighted new AI infrastructure partnerships, while ServiceNow received a fresh Buy rating from Bank of America.
Nvidia’s Earnings Could Make or Break the AI Stock Trade

Nvidia’s Earnings Could Make or Break the AI Stock Trade

19 May 2026
Nvidia rose 0.8% ahead of its earnings report, while CoreWeave dropped 3.7% after Google and Blackstone announced a $5 billion U.S. AI cloud venture using Google’s custom TPUs. The new venture will offer 500 megawatts of data-center capacity by 2027. AMD and Micron also gained, but Microsoft and Broadcom slipped. Investors are watching whether Nvidia can maintain dominance as competition in AI inference intensifies.
Go toTop